2 Comments
⭠ Return to thread

Pharmas must be ostracized. SV40's is noted within c19s, so the makers are yet killing monkeys today. Plenty of evidence as the very existence of fake Vaccine courts was set up to preclude massive Pharma payouts for many vax injuries, mainly autism and SV40 brain, lung and blood cancers. These guys are conditioned to destroy American lives and pay out very little due to the rigged court system. And so they just keep injuring people to groom all for the big cull.

Expand full comment

Full blown SARS-CoV-2 disease takes years to incubate. Partial disease, e.g., thyroid disease (see, e.g., at link below), neurodegenerative disease, gall bladder disease etc comes on much quicker. Organs are aged prematurely and every organ system is attacjed. Cumulative exposures accelerate the damage. Boosters need to be rolled out for 3 main reasons: 1) Shrestha et al's data show repeat vaccination predicts testing positive for the SARS-CoV-2 prodrome (so called COVID-19) of the oncogenic and immunocompromising disease; 2) repeat vaccinations cause a class switch to IgG4 which is associated with cancer promotion and autoimmune disease including autoimmune myocarditis; & 3) the probabilty of Adverse Events Following Inoculation increases with increasing numbers of inoculations and mRNA disease includes many of the same diseases as those caused directly by the virus.

"The aim of the present study was to assess the post-COVID-19 effects on thyroid function in patients without history of thyroid disease after complete recovery from mild-to-moderate COVID-19 ... Thyroid dysfunction was registered in 61.1% of the patients (78.3% subclinical hypothyroidism, 13% subclinical hyperthyroidism and 8.7% overt hypothyroidism) two months after COVID-19 ... Our findings indicate that COVID-19 could have long-term, negative effects on thyroid function. Therefore, thyroid function testing should be included in the follow-up algorithm of COVID-19 survivors."

Thyroid dysfunction as a long-term post-COVID-19 complication in mild-to-moderate COVID-19

https://www.tandfonline.com/doi/full/10.1080/13102818.2023.2170829

Expand full comment